Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AP304
- Development stage
- Preclinical
- Lead developer
- Alebund Pharmaceuticals
01
Overview
AP304 is a preclinical drug candidate being developed by Alebund Pharmaceuticals for the treatment of acute kidney injury (AKI) and acute ischemic stroke (AIS). Alebund Pharmaceuticals is a biopharmaceutical company focused on discovering and developing innovative therapies for kidney diseases and their complications. While some early reports associated the AP304 program with autosomal dominant polycystic kidney disease (ADPKD), the company's official pipeline identifies AKI and AIS as the primary target indications. The specific mechanism of action, biological target, and modality (whether small molecule or biologic) have not been publicly disclosed by the developer.
Beyond the preview
Go deeper on AP304.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AP304.